Mitochondrial complex II mutated SDHD cell line
Invented by Abey Bandara
Invented at Virginia Tech
- References (1)
- Inventor Info
|Antigen/Gene or Protein Targets
|Mitochondrial disease; complex II deficiency; Paraganglioma
The HEK293ΔSDHD cell line expresses a CRISPR/Cas9 mutated nuclear encoded subunit, SDHD, of mitochondrial complex II (succinate dehydrogenase). This cell line has been shown to significantly alter the function of complex II (CII) of the mitochondrial electron transport chain and displays disruptions to SDHD that mimic clinical presentations of CII deficiency. These cells represent a powerful model of metabolic pathologies, not only for mitochondrial disease, but also for understanding the importance of CII in developing novel therapeutics.
Specific disruptions in SDHD have been reported to present clinically as the following disease conditions:
-Complex II deficiency
|The cell line is currently stored at Virginia Tech.
|Cancer, Drug Discovery & Development, Metabolism
|The mutant has been shown to grow much slower than the parental cell line. The doubling time of the mutant is also significantly slower than that of the parental line.
|Recommended Growing Conditions
|DMEM medium supplemented with 10% Fetal Bovine Serum and 1% Penicillin-Streptomycin at 37ºC temperature and 5-6% CO2.
|HEK293 parental line
CRISPR edited HEK293 cells.
Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here
This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.
There are 1 reference entries for this reagent.View All References